Navigation Links
Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
Date:3/22/2012

t 8:25 AM.

About PCSK9
PCSK9 is known to be a determinant of circulating LDL levels, as it binds to LDL receptors resulting in their degradation so that fewer are available on liver cells to remove excess LDL-cholesterol from the blood.  Moreover, traditional LDL-lowering therapies such as statins actually stimulate the production of PCSK9, which may limit their ability to lower LDL-cholesterol.  Blocking the PCSK9 pathway is therefore a potentially novel mechanism for lowering LDL-cholesterol.

About REGN727
REGN727/SAR236553 is a fully-human monoclonal antibody directed against PCSK9, administered via subcutaneous injection.  By inhibiting PCSK9, a determinant of circulating LDL-cholesterol levels in the blood, REGN727 increases the number of free LDL receptors which can bind to circulating LDL and clear it from the bloodstream.  REGN727 was created using Regeneron's pioneering VelocImmune® technology and is being developed by Regeneron in collaboration with Sanofi.

About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, one for the treatment of neovascular (wet) age-related macular degeneration and another for the treatment of a rare inflammatory condition.  Additionally, Regeneron has three regulatory applications pending before the U.S. Food and Drug Administration (FDA) and 10 drug candidates in clinical development.  More information and recent news releases are available on the Regeneron web site at www.regeneron.com

Regeneron Forward-Looking Statement
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performan
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , 21. Mai 2013 ... die die Firmen OMNIlife science® Inc., Enztec Ltd. ... hat zwei neue, erfahrene Mitglieder in die ... , eine erfahrene Führungspersönlichkeit aus der Orthopädie, ... David Johnson , anerkannter Experte ...
(Date:5/21/2013)... mayo de 2013 La junta directiva ... incluyen OMNIlife science®, Inc., Enztec, Ltd. y Praxim, SA, ... junta. Guy Mayer, un ejecutivo ortopédico experimentado, será vicepresidente ... Johnson , un experto refutado en dispositivos ... de unirse a OSI como presidente de la ...
(Date:5/21/2013)... Calif. , May 21, 2013 RenovoRx ... prestigious 2013 TiE50 "Top Startup" Award at TiEcon 2013, ... innovation, strong management team and quality of entrepreneurial ideas. ... at the Santa Clara Convention ... highly influential list of the most enterprising startup companies ...
Breaking Medicine Technology:Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3RenovoRx Named Winner of 2013 TiE50 "Top Startup" 2
... Arbor Pharmaceuticals announced today that it has filed ... Food and Drug Administration (FDA).  The recently filed product ... which provides seven years of market exclusivity. In addition, ... this product primarily due to the safety advantages it ...
... MADISON, Wis., Dec. 1, 2011 Novelos Therapeutics, Inc. ... treatment and diagnosis of cancer, today announced the pricing of ... unit for gross proceeds of $5,904,000.  Each unit consists of ... one share of common stock.  The warrants will have an ...
Cached Medicine Technology:Arbor Pharmaceuticals Announces Filing of First NDA 2Novelos Therapeutics Prices $5.9 Million Public Offering 2
(Date:5/21/2013)... Calabash, NC (PRWEB) May 21, 2013 ... Lodges is synonymous with comprehensive travel guides. Brunswick Plantation ... play golf packages that include access to 27 holes ... available golf courses in North Carolina, knowing the ... Resorts and Lodges takes away the overwhelming task of ...
(Date:5/21/2013)... (PRWEB) May 22, 2013 About one ... the Fertility Clinics industry one of the ... assists patients who are unable to conceive naturally through ... popular of which is in-vitro fertilisation (IVF) cycles. Over ... cycles in Australia has increased by 4.4% per annum ...
(Date:5/21/2013)... Steven Reinberg HealthDay Reporter , , TUESDAY, May ... a major cause of sleep apnea in children, and ... learning for these kids, it did help them with ... finds. Sleep apnea is a condition that causes ... a greater improvement in sleep with the surgery, and ...
(Date:5/21/2013)... University of Iowa,s vice president for research and ... exascale computing, the next generation of supercomputers designed ... to the human mind. , Daniel Reed will ... of the House Subcommittee on Energy, titled, "America,s ... begins at 10 a.m. in Room 2318 of ...
(Date:5/21/2013)... Norton HealthDay Reporter , , TUESDAY, May 21 ... two genes may be at increased risk of suffering ... The researchers hope they can use the findings ... pregnant women who are vulnerable to postpartum depression, which ... study, reported in the May 21 issue of the ...
Breaking Medicine News(10 mins):Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3Health News:Iowa VP for Research addresses next-generation supercomputers at congressional hearing 2Health News:Genes May Boost Woman's Risk of Postpartum Depression 2Health News:Genes May Boost Woman's Risk of Postpartum Depression 3
... FUND RESEARCH TO CURE CANCER IN ... DOGS - RESEARCH ALSO BENEFITING HUMANS, DENVER, Jan. 18 ... dogs and or very special humans in your life.,Morris Animal Foundation ... contributing $50 or more to the MAF canine,cancer cure research effort. ...
... LifeSync Corporation is,pleased to announce the appointment of ... McLane comes to LifeSync Corporation after,seven years at ... she,most recently held the position of Executive Director ... McLane spent over 13,years at C.R. Bard in ...
... by Christian Rocker and Top ,Clean, Comedian Round Out the All-Star ... ... 18 Our Savior Lutheran Church,announced today an all-star line-up for its ... Sure to satisfy all in,attendance, LoveFest offers its most diverse casting to ...
... dual implantation of radioactive seeds and chemotherapy wafers ... led by specialists at the Neuroscience Institute at ... , The study, published in the February issue ... treated with simultaneous implantation of radioactive seeds and ...
... are aimed at getting action from Cardinal George and Public Official ... ... 17 Three years ago, health care activist,Joe Novak -- during a ... end the abuses of not-for-profit health,care systems, especially those that are Catholic., ...
... Medical,Center has held extensive settlement discussions with the Public ... their apparent negotiating,tactic we remain optimistic that these discussions ... The filing of a lawsuit was unnecessary given the ... not receive any document outlining,Mr. Olvera,s specific claims until ...
Cached Medicine News:Health News:Unique Gift for Valentine's Day: Canine Cancer Campaign Customized Dog Tag - for Your Dog or as a Beautiful Piece of Jewelry for a Special Human 2Health News:LifeSync Corporation Appoints Nancy McLane as Senior Vice President Operations 2Health News:LoveFest 6 Taps Hollywood Actress to Headline Annual Abstinence Conference 2Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2Health News:Ad Campaign Targets Abuses by Not-For-Profits 2Health News:Hollywood Presbyterian Medical Center Responds to ACLU Lawsuit 2
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Inquire...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
Medicine Products: